The filing is a routine quarterly update with no material financial surprises. Traders should monitor upcoming clinical data readouts for MP0712 expected in 2026 and 2027, as these are the primary value-driving catalysts. The cash runway into late 2027 provides a buffer, but the lack of revenue and continued operating losses mean the stock remains highly dependent on pipeline success.
Price Chart
Executive Summary
Molecular Partners AG reported H1 2026 financial results, showing a net loss of CHF 26.7 million (improved from CHF 37.2 million in H1 2025) with no revenue. The company highlighted progress in its lead Radio-DARPin candidate MP0712, which advanced to a higher dose level in a Phase 1/2a study for small cell lung cancer, and selected CD70 as a new radio target. Cash and cash equivalents stood at CHF 67.9 million, expected to fund operations into late 2027. The filing is a routine interim financial update with no material financial data to suggest a change in the company's trajectory, though the clinical pipeline progress is a positive development.
Key Facts
- Net loss for H1 2026 was CHF 26.7 million, compared to CHF 37.2 million in H1 2025.
- Cash and cash equivalents were CHF 67.9 million as of June 30, 2026.
- Lead candidate MP0712 (DLL3-targeting Radio-DARPin) advanced to cohort 2 (higher dose level) in a Phase 1/2a study.
- CD70 was selected as a new radio target for kidney cancer, with clinical program start anticipated in 2027.
- Total operating expenses for H1 2026 were CHF 27.0 million, down from CHF 33.5 million in H1 2025.
- The company expects to be funded into late 2027.
- No revenue was reported for H1 2026 or H1 2025.
Financial Impact
Net loss improved by CHF 10.5 million year-over-year, driven by lower operating expenses. Cash burn (net cash used in operating activities) was CHF 25.0 million in H1 2026.
Risk Factors
- Clinical trial failure or delay for MP0712 or other pipeline candidates.
- Cash burn may require future dilutive financing if milestones are not met.
- No revenue stream, making the company entirely dependent on partnership payments and capital markets.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001745114-26-000028 |
| Document: 0001745114-26-000028-index.html | 0001745114-26-000028 |
| Document: 0001745114-26-000028.txt | 0001745114-26-000028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 9w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.81 (−13.01%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.81 (−4.75%) |
Jul 16, 2026 14w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.81 (−7.07%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.81 (−4.75%) |
Jul 2, 2026 16w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jul 2, 2026 16w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.81 (−3.54%) |
May 12, 2026 24w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.81 (−4.75%) |
May 1, 2026 25w ago | Press Release | $4.24 $3.95 | ▼ −6.84% | ▼ −12.12% | $3.81 (−10.14%) |
Mar 30, 2026 30w ago | 6-K | $3.93 $4.28 | ▲ +8.91% | ▼ −3.69% | $3.81 (−3.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers